

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT6260209

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
RICHARD JOHN BUICK	04/13/2018
RECEIVING PARTY DATA	
Name:	FUSION ANTIBODIES PLC
Street Address:	C/O TUGHANS SOLICITORS
Internal Address:	MARLBOROUGH HOUSE, 30 VICTORIA STREET
City:	BELFAST
State/Country:	NORTHERN IRELAND
Postal Code:	U.K. BT1 3GG
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	16763185
CORRESPONDENCE DATA	
Fax Number:	(202)371-2540
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	2023712600
Email:	karenm@sternekessler.com,yparker@sternekessler.com
Correspondent Name:	STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.
Address Line 1:	1100 NEW YORK AVENUE, NW
Address Line 4:	WASHINGTON, D.C. 20005
ATTORNEY DOCKET NUMBER:	1861.4270001/JMC/KRM
NAME OF SUBMITTER:	KAREN R. MARKOWICZ
SIGNATURE:	/Karen R. Markowicz #36,361/
DATE SIGNED:	08/20/2020
Total Attachments: 2	
source=2020-08-19-Assignment-Buick-Fusion-Antibodies-plc-1861-4270001#page1.tif	
source=2020-08-19-Assignment-Buick-Fusion-Antibodies-plc-1861-4270001#page2.tif	

ASSIGNMENT

In consideration of the sum of One Dollar (\$1.00) or equivalent and other good and valuable consideration paid to the undersigned inventor: **Richard John BUICK**, hereby sells and assigns to **Fusion Antibodies plc**, a corporation formed under the laws of NORTHERN IRELAND, whose mailing address is C/O Tughans Solicitors, Marlborough House, 30 Victoria Street, Belfast, NORTHERN IRELAND, U.K. BT1 3GG (hereafter referred to as the Assignee), his/her entire right, title and interest, including the right to sue for past infringement and to collect for all past, present and future damages, for the United States of America (as defined in 35 U.S.C. § 100) and throughout the world,

(a) in the invention(s) known as **HUMANIZED ANTIBODIES TARGETING HUMAN TISSUE FACTOR** for which a provisional application for patent in the United States of America was filed on November 27, 2017 (also known as United States Application No. 62/591,168), in any and all non-provisional applications therefrom, in any and all Letters Patent(s) granted from such non-provisional applications, and

(b) in any and all applications that claim the benefit of the patent application listed above in part (a), including non-provisional applications, continuing (continuation, divisional, or continuation-in-part) applications, reissues, extensions, renewals and reexaminations of the patent application or Letters Patent therefor listed above in part (a), to the full extent of the term or terms for which Letters Patents issue, and

(c) in any and all inventions described in the patent application listed above in part (a), and in any and all forms of intellectual and industrial property protection derivable from such patent application, and that are derivable from any and all continuing applications, reissues, extensions, renewals and reexaminations of such patent application, including, without limitation, patents, applications, utility models, inventor's certificates, and designs together with the right to file applications therefor; and including the right to claim the same priority rights from any previously filed applications under the International Agreement for the Protection of Industrial Property, or any other international agreement, or the domestic laws of the country in which any such application is filed, as may be applicable;

all such rights, title and interest to be held and enjoyed by the above-named Assignee, its successors, legal representatives and assigns to the same extent as all such rights, title and interest would have been held and enjoyed by the undersigned inventor had this assignment and sale not been made.

The undersigned inventor agrees to execute all papers necessary in connection with the application(s) and any non-provisional, continuing (continuation, divisional, or continuation-in-part), reissue, reexamination or corresponding application(s) thereof and also to execute separate

assignments in connection with such application(s) as the Assignee may deem necessary or expedient.

The undersigned inventor agrees to execute all papers necessary in connection with any judicial or administrative proceeding, including but not limited to an interference, derivation, post-grant proceeding, or patent enforcement action (judicial or otherwise) related to the application(s) or any non-provisional, continuing (continuation, divisional, or continuation-in-part), reissue or reexamination application(s) thereof or Letters Patent(s) therefor and to cooperate with the Assignee in every way possible in obtaining evidence and assisting with such judicial or administrative proceeding.

The undersigned inventor hereby represents that he/she has full right to convey the entire interest herein assigned, and that he/she has not executed, and will not execute, any agreement in conflict therewith.

The undersigned inventor hereby grants the patent practitioners associated with CUSTOMER NUMBER 101416 the power to insert in this assignment any further identification that may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office for recordation of this document.

The undersigned inventor hereby represents that he/she understands that the patent practitioners associated with CUSTOMER NUMBER 101416 are the legal representatives of, and attorneys for, the assignee, and are NOT the legal representatives of, and attorneys for, the inventor.

IN WITNESS WHEREOF, executed by the undersigned inventor on the date opposite his/her name.

Date: 13th APRIL 2018 Signature of Inventor: R. Buick
Richard John BUICK

SIGNED on behalf of the said ASSIGNEE,

FUSION ANTIBODIES PLC

By: Paul H. Kern
Name: PAUL KERN
Title: CEO
Date: 13/4/18